Generation of genetically engineered CHO cell lines to support the production of a difficult to express therapeutic protein

Selection of CHO host and recombinant cell pools by inhibition of the proteasome results in enhanced product yields and cell specific productivity

“…CHO cell expression systems and associated bioprocesses have been developed through a range of approaches over the last few decades such that yields in excess of 5 g/L of mAb are now routinely achieved (Marichal-Gallardo, 2012). However, some mAbs are still difficult to express (DTE) in CHO cells (Laux, 2013;Mathias, 2020;Pybus, 2014) whilst many novel biotherapeutic molecule formats in development are DTE in CHO cells, or any other, expression system. A number of approaches have been taken to try and address this so that such DTE proteins can be produced at higher yields and quality.…”